Skip to main content
. Author manuscript; available in PMC: 2015 Sep 7.
Published in final edited form as: Cell Transplant. 2014 Mar 7;24(8):1599–1614. doi: 10.3727/096368914X678571

Figure 6.

Figure 6

RMT4-53 treatment was evaluated in diabetes prevention in NOD mice. No effect was observed on the onset of diabetes after RMT4-53 treatment (A). An increase in the percentage of B-cells (but not of DCs) positive for TIM4 cells was observed in RMT4-53-treated mice compared to untreated mice (n=3, *p<0.05; B, C). An increase in the number of IFN-γ-producing cells was observed in RMT4-53-treated mice during BDC2.5 (n=5, *p<0.05 vs. untreated; D) and IGRP challenge (n=5, *p<0.05 vs. untreated; D) compared to untreated mice. An increase in the number of IL-4-producing cells was observed as well (BDC2.5 peptide: n=5, *p<0.05 vs. untreated; IGRP: n=5, *p<0.05 vs. untreated; E). The ratio of Th2/Th1 shows a significant skewing toward a Th2 response only with IGRP peptide challenge (n=5, *p<0.05 vs. untreated; F). No effect was observed on the percentage of Th17 cells (G), while a slight decrease in the percentage of T effector cells in RMT4-53-treated compared to untreated mice was observed (n=3, *p<0.05 vs. untreated; H). The percentage of Tregs was unchanged (I).